XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
$ / shares in Thousands, $ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Unrestricted cash and cash equivalents $ 444,809 $ 339,338
Restricted cash and cash equivalents 37,494 44,315
Loans, interest and fees receivable, at fair value 2,150,636 2,173,759
Notes payable, at face value $ 1,862,518 $ 1,861,685
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 14,792,159 14,603,563
Common stock, outstanding (in shares) 14,792,159 14,603,563
Series A Preferred Stock [Member]    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 400,000 400,000
Preferred stock, shares outstanding (in shares) 400,000 400,000
Preferred stock, liquidation preference $ 40,000 $ 40,000
Series B Preferred Stock [Member]    
Preferred stock, no par value (in dollars per share) $ 0 $ 0
Preferred stock, shares issued (in shares) 3,300,704 3,256,561
Preferred stock, shares outstanding (in shares) 3,300,704 3,256,561
Preferred stock, liquidation preference $ 82,500 $ 81,400
Variable Interest Entity, Primary Beneficiary [Member]    
Unrestricted cash and cash equivalents 177,200 158,000
Restricted cash and cash equivalents 19,700 20,500
Loans, interest and fees receivable, at fair value 2,107,000 2,128,600
Notes payable, at face value $ 1,795,400 $ 1,795,900